LTB NG 6
Alternative Names: Gonorrhoea vaccine - Griffith University/LimmaTech Biologics; LTB-NG6; Multivalent gonorrhoea vaccine - LimmaTech Biologics; N. gonorrhoeae vaccine - LimmaTech BiologicsLatest Information Update: 19 Aug 2026
At a glance
- Originator LimmaTech Biologics
- Class Bacterial vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gonorrhoea
Most Recent Events
- 30 Jul 2026 Phase-I clinical trials in Gonorrhoea (Prevention) in Germany (Parenteral) (CTIS2026-526168-19-00) (NCT07758972)
- 07 Jul 2026 LimmaTech Biologics plans a phase I trial in Gonorrhoea (Prevention) in Germany in July 2026 (Parenteral) (CTIS2026-526168-19-00)
- 01 Nov 2022 LimmaTech Biologics has patent protection for Gonorrhoea vaccine in USA